Sign In
Buy BIIB
$164.68
-2.87 (-1.71%)
At Close: Nov 17, 2025
BEDFORD, Mass., & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with
– Despite treatment with standard-of-care anti-seizure medicines, children with Dravet syndrome experienced high seizure burden and plateaued in neurodevelopment, resulting in a widening gap relativ
High Dose Regimen of Nusinersen Receives Positive CHMP Opinion for the Treatment of Spinal Muscular Atrophy
06:00am, Monday, 17'th Nov 2025
CAMBRIDGE, Mass., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted
Biogen Completes Acquisition of Alcyone Therapeutics
04:05pm, Friday, 14'th Nov 2025
CAMBRIDGE, Mass., Nov. 14, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) has completed the acquisition of Alcyone Therapeutics, a clinical-stage biotechnology company known for its innovative CN
Biogen Inc. (BIIB) Presents at TD Cowen Immunology and Inflammation Summit Transcript
06:41pm, Thursday, 13'th Nov 2025
Biogen Inc. ( BIIB ) TD Cowen Immunology and Inflammation Summit November 13, 2025 4:30 PM EST Company Participants Diana Gallagher Conference Call Participants Philip Nadeau - TD Cowen, Research Divi
“LEQEMBI®” (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease Approved in the United Kingdom
06:30pm, Thursday, 13'th Nov 2025
TOKYO and CAMBRIDGE, Mass., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Mas
Dow Cools From Record; Nasdaq Swimming in Red Ink
12:14pm, Thursday, 13'th Nov 2025
The Dow and Nasdaq are sporting steep midday losses, despite the end of the longest government shutdown in history
Biogen Inc. (BIIB) Presents at Wedbush Rewind ASN 2025 Conference Prepared Remarks Transcript
05:01pm, Monday, 10'th Nov 2025
Biogen Inc. ( BIIB ) Wedbush Rewind ASN 2025 Conference November 10, 2025 1:20 PM EST Company Participants Uptal Patel - Chief Medical Officer Conference Call Participants Laura Chico - Wedbush Securi
Arkadios Wealth Advisors Sells 351 Shares of Biogen Inc. $BIIB
04:02am, Thursday, 06'th Nov 2025
Arkadios Wealth Advisors decreased its stake in shares of Biogen Inc. (NASDAQ: BIIB) by 10.5% during the undefined quarter, according to the company in its most recent 13F filing with the Securities a
Biogen to Highlight Scientific Progress in Rare Kidney Disease at American Society of Nephrology (ASN) Kidney Week 2025
07:30am, Monday, 03'rd Nov 2025
CAMBRIDGE, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) – will present new data from its felzartamab clinical development programs at Kidney Week 2025, the American Society of
Bessemer Group Inc. Has $444,000 Holdings in Biogen Inc. $BIIB
05:22am, Monday, 03'rd Nov 2025
Bessemer Group Inc. grew its stake in Biogen Inc. (NASDAQ: BIIB) by 16.7% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission
Biogen Inc. (BIIB) Q3 2025 Earnings Call Transcript
09:16pm, Thursday, 30'th Oct 2025
Biogen Inc. ( BIIB ) Q3 2025 Earnings Call October 30, 2025 8:30 AM EDT Company Participants Tim Power - Head of Investor Relations Christopher Viehbacher - President, CEO & Director Priya Singhal - E
BIIB Beats on Q3 Earnings & Sales, Stock Down on Lowered '25 EPS View
03:06pm, Thursday, 30'th Oct 2025
Biogen's Q3 earnings and sales top estimates on strong drug demand, but shares slide after the company cuts its 2025 EPS forecast.
Biogen (BIIB) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
10:31am, Thursday, 30'th Oct 2025
While the top- and bottom-line numbers for Biogen (BIIB) give a sense of how the business performed in the quarter ended September 2025, it could be worth looking at how some of its key metrics compar
Biogen Inc. (BIIB) Q3 Earnings and Revenues Top Estimates
08:16am, Thursday, 30'th Oct 2025
Biogen Inc. (BIIB) came out with quarterly earnings of $4.81 per share, beating the Zacks Consensus Estimate of $3.89 per share. This compares to earnings of $4.08 per share a year ago.
